Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-25 | Bachelor of Arts in Biology from Fisk University; Co-founder, President and CEO of Kodikaz Therapeutic Solutions, a gene therapy company. |
| 2023-04-25 | M.B.A. from Manchester Business School, Manchester, UK. Bachelor of Arts in Biology from Fisk University. President and CEO of Kodikaz Therapeutic Solutions, Inc., a gene therapy company. |
| 2023-08-29 | Anthony Johnson (6) Management and Directors: Number of Shares Beneficially Owned: 6,121 Percentage Beneficially Owned: * |
| 2023-12-12 | Anthony Johnson(6) 6,121 shares beneficially owned, no mention of technical skills or software background. |
| 2024-04-29 | Mr. Johnson is co-founder, President, and CEO of Kodikaz Therapeutic Solutions, a next-generation non-viral gene therapy company. He is also a founding partner of Buffalo Biosciences in 2006 a life science strategic business management firm that supports the evaluation and commercialization of bioscience technologies from concept to market. Previously he was President and CEO of Empire Genomics, an oncology molecular diagnostic testing company, from 2006 until 2019. He also served as the business leader of the stem cell and regenerative medicine franchise for Thermo Fisher (Invitrogen Corporation). Anthony has leveraged his business experience and numerous board positions to mentor technology startups and entrepreneurs, spur state and local job creation, and introduce STEM curriculum into early childhood education. Mr. Johnson is a founding board member of the Communities of Giving Legacy Initiative, which works to create positive change in the lives of low-income youth of color. Additionally, he serves as Michigan Street African-American Heritage Corridor Commissioner and was an Opportunities Council member for University of Buffalo. He holds an MBA from Manchester Business School, Manchester, UK, with an emphasis in international strategy, and a BA in biology from Fisk University, Nashville, TN. |
| 2024-10-25 | Anthony Johnson |
Data sourced from SEC filings. Last updated: 2026-03-09